Caplin Point Laboratories Croissance future

Future contrôle des critères 2/6

Caplin Point Laboratories devrait augmenter ses bénéfices et son chiffre d'affaires de 14.8% et de 13.7% par an respectivement. Le BPA devrait croître de de 14.8% par an. Le rendement des capitaux propres devrait être 18.4% dans 3 ans.

Informations clés

14.8%

Taux de croissance des bénéfices

14.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	18.3%
Taux de croissance des recettes	13.7%
Rendement futur des capitaux propres	18.4%
Couverture par les analystes	Low
Dernière mise à jour	19 Oct 2024

Mises à jour récentes de la croissance future

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Recent updates

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 31

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

Sep 12

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Aug 11

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Aug 10

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Jul 12

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

May 24

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

May 04

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Mar 07

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Oct 24

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Sep 15

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Aug 11

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Sep 23

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 11

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Jul 22

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

May 15

A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Jan 21

Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?

Oct 20

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50

Sep 17

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50

Sep 03

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price

Aug 27

Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?

Jun 12

Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Apr 29

Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?

Mar 24

Prévisions de croissance des bénéfices et des revenus

NSEI:CAPLIPOINT - Estimations futures des analystes et données financières antérieures (INR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	25,686	7,190	N/A	N/A	2
3/31/2026	22,140	5,920	3,796	N/A	3
3/31/2025	19,349	5,147	3,504	N/A	3
6/30/2024	17,577	4,776	N/A	N/A	N/A
3/31/2024	16,961	4,571	1,726	3,184	N/A
12/31/2023	16,318	4,376	N/A	N/A	N/A
9/30/2023	15,683	4,179	399	2,593	N/A
6/30/2023	15,157	3,947	N/A	N/A	N/A
3/31/2023	14,683	3,763	779	2,714	N/A
12/31/2022	14,182	3,532	N/A	N/A	N/A
9/30/2022	13,724	3,307	2,305	3,467	N/A
6/30/2022	13,153	3,140	N/A	N/A	N/A
3/31/2022	12,710	2,998	2,456	3,367	N/A
12/31/2021	12,099	2,872	N/A	N/A	N/A
9/30/2021	11,581	2,767	1,288	2,044	N/A
6/30/2021	11,217	2,586	N/A	N/A	N/A
3/31/2021	10,624	2,423	1,953	2,686	N/A
12/31/2020	9,986	2,248	N/A	N/A	N/A
9/30/2020	9,524	2,189	1,650	1,877	N/A
6/30/2020	9,107	2,193	N/A	N/A	N/A
3/31/2020	8,640	2,150	-321	447	N/A
12/31/2019	8,356	2,159	N/A	N/A	N/A
9/30/2019	7,664	2,032	-331	830	N/A
6/30/2019	6,948	1,894	N/A	N/A	N/A
3/31/2019	6,490	1,766	182	834	N/A
12/31/2018	6,048	1,621	N/A	N/A	N/A
9/30/2018	5,874	1,538	N/A	N/A	N/A
6/30/2018	5,628	1,459	N/A	N/A	N/A
3/31/2018	5,399	1,448	N/A	665	N/A
12/31/2017	5,145	1,430	N/A	N/A	N/A
9/30/2017	4,757	1,297	N/A	N/A	N/A
6/30/2017	4,401	1,165	N/A	N/A	N/A
3/31/2017	4,016	956	N/A	676	N/A
12/31/2016	3,655	783	N/A	N/A	N/A
9/30/2016	3,420	703	N/A	N/A	N/A
6/30/2016	3,238	619	N/A	N/A	N/A
3/31/2016	3,088	584	N/A	565	N/A
12/31/2015	2,906	535	N/A	N/A	N/A
9/30/2015	2,722	465	N/A	N/A	N/A
6/30/2015	2,518	410	N/A	499	N/A
3/31/2015	2,296	353	N/A	N/A	N/A
12/31/2014	2,074	318	N/A	N/A	N/A
9/30/2014	1,893	305	N/A	N/A	N/A
6/30/2014	1,731	258	N/A	598	N/A
3/31/2014	1,643	204	N/A	N/A	N/A
12/31/2013	1,517	167	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CAPLIPOINT ( 14.8% par an) est supérieure au taux d'épargne ( 6.7% ).

Bénéfices vs marché: Les bénéfices de CAPLIPOINT ( 14.8% par an) devraient croître plus lentement que le marché Indian ( 18.1% par an).

Croissance élevée des bénéfices: Les bénéfices de CAPLIPOINT devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CAPLIPOINT ( 13.7% par an) devrait croître plus rapidement que le marché Indian ( 10.2% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CAPLIPOINT ( 13.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de CAPLIPOINT devrait être faible dans 3 ans ( 18.4 %).

Caplin Point Laboratories Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 14% to ₹2,142

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Price target increased by 17% to ₹1,717

Price target increased by 8.0% to ₹1,076

Price target increased to ₹948

Recent updates

Caplin Point Laboratories Limited to Report Q2, 2025 Results on Nov 07, 2024

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Price target increased by 14% to ₹2,142

Upcoming dividend of ₹2.50 per share

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50

Price target increased by 17% to ₹1,717

Dividend of ₹2.50 announced

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited, Annual General Meeting, Sep 30, 2024

Caplin Point Laboratories Limited to Report Q1, 2025 Results on Aug 07, 2024

Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer

Investor sentiment improves as stock rises 18%

Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues

Full year 2024 earnings: Revenues in line with analyst expectations

Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024

Caplin Point Laboratories Limited to Report Fiscal Year 2024 Results on May 16, 2024

Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?

Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement

Third quarter 2024 earnings released: EPS: ₹15.44 (vs ₹12.86 in 3Q 2023)

Caplin Point Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024

Investor sentiment improves as stock rises 16%

Price target increased by 8.0% to ₹1,076

Second quarter 2024 earnings released: EPS: ₹15.13 (vs ₹12.09 in 2Q 2023)

Caplin Point Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case

Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023

Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise

Upcoming dividend of ₹2.50 per share at 0.5% yield

Caplin Point Laboratories Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 15%

Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

First quarter 2024 earnings released: EPS: ₹13.62 (vs ₹11.21 in 1Q 2023)

Caplin Point Laboratories Limited to Report Q1, 2024 Results on Aug 07, 2023

Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP

Upcoming dividend of ₹2.00 per share at 0.3% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Caplin Point Laboratories Limited to Report Q4, 2023 Results on May 24, 2023

Now 20% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: ₹12.86 (vs ₹9.90 in 3Q 2022)

Caplin Point Laboratories Limited to Report Q3, 2023 Results on Feb 11, 2023

Price target increased to ₹948

Caplin Point Laboratories Limited (BSE:524742) acquired API plant in Vizag from Metrochem API Private Limited.

Second quarter 2023 earnings released: EPS: ₹12.09 (vs ₹9.91 in 2Q 2022)

Caplin Point Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022

Caplin Point Laboratories Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited Announces Change in Directorate

We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise

Upcoming dividend of ₹2.00 per share

Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited, Annual General Meeting, Sep 29, 2022

Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released: EPS: ₹11.21 (vs ₹9.37 in 1Q 2022)

Caplin Point Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?

Caplin Point Laboratories Limited Announces Resignation of D P Mishra as Non-Executive, Non-Independent Director

Investor sentiment improved over the past week

Upcoming dividend of ₹2.00 per share

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00

Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year Ended March 31, 2022

Caplin Point Laboratories Limited to Report Fiscal Year 2022 Results on May 12, 2022

Insufficient new directors